DDI+ Benefits

DDI+: Major benefits to providers, healthcare professionals (HCPs), and patients

DDI+ is a comprehensive, personalized, and easy-to-use software platform that makes a difference when managing drug-related problems. It significantly reduces futile alerts to optimize the HCP’s experience and patient’s care. All this while ensuring safe drug prescription, expected clinical outcome, and a proven reduction in healthcare expenditure.

DDI+ key benefits:

Personalized and dynamic alerting
DDI+ alerts in ‘at-risk populations’ by considering hundreds of patient specific factors/modifiers (e.g., DNA profile, ECG recordings, diet, smoking, age, allergies, lab results, renal/liver functions, vital signs, drugs’ serum levels, dispensing characteristics). This enables a decrease in alert fatigue up to 95%17, 18, while generating an outstanding ratio of true-positive vs. false positive alerts17.


Backed by globally-acknowledged expertise

First Data Bank (FDB) – a comprehensive & professional screening tool, which focuses on the clinical relevance of potential interactions

University of Washington – relying on the unique know-how of DIDB (Pharmacokinetic Database) & ePKGene (Pharmacogenetic Database) as well as incorporating the use of mechanism-based inference in order to personalize the assessments

Hansten & Horn – advice from globally acknowledged drug interaction specialists


One glance operation
An innovative graphic user interface that enables, in seconds, to promptly detect, prioritize and solve DRPs.


Very high ‘Signal-to-Noise’ ratio17; Alert fatigue minimization

Derived from a unique, 3-tier mechanism that generates a high true-positive vs false-positive alerting ratio while substantially decreasing alert load. This is in contrast to a very high ‘Noise-to-Signal’ alert ratio in current solutions.


Alternative drug(s) mechanism
DDI+ presents alternative drug(s) to problematic combinations, based on its unique mechanism and by considering various patient associated factors. The alternatives are sorted by their potential to generate alerts/safety issues.


Multi-drug assessment of designated interactions
In contrary to binary assessments.


Substantial impact on healthcare/economics
Proven to reduce hospitalizations (-5.6%), drug consumption (-1.5%) & imaging procedures (-2.1%)16.     



16. Large-scale, community-based trial of a personalized drug-related problem rectification system. kahan et al., American Journal of Pharmacy Benefits 2017; 9(2):41-6.

17. Meuhedet Health Services (Israel)  – Analysis of 300 polypharmacy patients; Nov 2016. In-house; Data (unpublished) from Meuhedet.

18. Leumit Health Services, Israel – Analysis of Aug 1-10, 2016 real-time alerts distribution. In-house data